PMID- 26484665
OWN - NLM
STAT- MEDLINE
DCOM- 20160607
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 10
DP  - 2015
TI  - Evidence for a Cystic Fibrosis Enteropathy.
PG  - e0138062
LID - 10.1371/journal.pone.0138062 [doi]
LID - e0138062
AB  - BACKGROUND: Previous studies have suggested the existence of enteropathy in 
      cystic fibrosis (CF), which may contribute to intestinal function impairment, a 
      poor nutritional status and decline in lung function. This study evaluated 
      enterocyte damage and intestinal inflammation in CF and studied its associations 
      with nutritional status, CF-related morbidities such as impaired lung function 
      and diabetes, and medication use. METHODS: Sixty-eight CF patients and 107 
      controls were studied. Levels of serum intestinal-fatty acid binding protein 
      (I-FABP), a specific marker for enterocyte damage, were retrospectively 
      determined. The faecal intestinal inflammation marker calprotectin was 
      prospectively studied. Nutritional status, lung function (FEV1), exocrine 
      pancreatic insufficiency (EPI), CF-related diabetes (CFRD) and use of proton pump 
      inhibitors (PPI) were obtained from the medical charts. RESULTS: Serum I-FABP 
      levels were elevated in CF patients as compared with controls (p<0.001), and 
      correlated negatively with FEV1 predicted value in children (r-.734, p<0.05). 
      Faecal calprotectin level was elevated in 93% of CF patients, and correlated 
      negatively with FEV1 predicted value in adults (r-.484, p<0.05). No correlation 
      was found between calprotectin levels in faeces and sputum. Faecal calprotectin 
      level was significantly associated with the presence of CFRD, EPI, and PPI use. 
      CONCLUSION: This study demonstrated enterocyte damage and intestinal inflammation 
      in CF patients, and provides evidence for an inverse correlation between 
      enteropathy and lung function. The presented associations of enteropathy with 
      important CF-related morbidities further emphasize the clinical relevance.
FAU - Adriaanse, Marlou P M
AU  - Adriaanse MP
AD  - Department of Paediatric Gastroenterology & Nutrition and Toxicology Research 
      Institute Maastricht (NUTRIM), Maastricht University Medical Centre, Maastricht, 
      the Netherlands.
FAU - van der Sande, Linda J T M
AU  - van der Sande LJ
AD  - Department of Paediatric Gastroenterology & Nutrition and Toxicology Research 
      Institute Maastricht (NUTRIM), Maastricht University Medical Centre, Maastricht, 
      the Netherlands.
FAU - van den Neucker, Anita M
AU  - van den Neucker AM
AD  - Department of Paediatric Gastroenterology & Nutrition and Toxicology Research 
      Institute Maastricht (NUTRIM), Maastricht University Medical Centre, Maastricht, 
      the Netherlands.
FAU - Menheere, Paul P C A
AU  - Menheere PP
AD  - Department of Immunodiagnostics, Central Diagnostic Laboratory, Maastricht 
      University Medical Centre, Maastricht, the Netherlands.
FAU - Dompeling, Edward
AU  - Dompeling E
AD  - Department of Paediatric Pulmonology, School for Public Health and Primary Care 
      (CAPHRI), Maastricht University Medical Centre, Maastricht, the Netherlands.
FAU - Buurman, Wim A
AU  - Buurman WA
AD  - Department of General Surgery, Maastricht University Medical Centre, Maastricht, 
      the Netherlands.
FAU - Vreugdenhil, Anita C E
AU  - Vreugdenhil AC
AD  - Department of Paediatric Gastroenterology & Nutrition and Toxicology Research 
      Institute Maastricht (NUTRIM), Maastricht University Medical Centre, Maastricht, 
      the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20151020
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (FABP2 protein, human)
RN  - 0 (Fatty Acid-Binding Proteins)
RN  - 0 (Leukocyte L1 Antigen Complex)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Cystic Fibrosis/*complications/metabolism/pathology
MH  - Fatty Acid-Binding Proteins/blood
MH  - Feces/chemistry
MH  - Female
MH  - Humans
MH  - Infant
MH  - Inflammation/complications/metabolism/pathology
MH  - Intestinal Diseases/*complications/metabolism/pathology
MH  - Leukocyte L1 Antigen Complex/analysis
MH  - Male
MH  - Middle Aged
MH  - Nutritional Status
MH  - Young Adult
PMC - PMC4617711
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/10/21 06:00
MHDA- 2016/06/09 06:00
PMCR- 2015/10/20
CRDT- 2015/10/21 06:00
PHST- 2014/10/06 00:00 [received]
PHST- 2015/08/25 00:00 [accepted]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
PHST- 2015/10/20 00:00 [pmc-release]
AID - PONE-D-14-42601 [pii]
AID - 10.1371/journal.pone.0138062 [doi]
PST - epublish
SO  - PLoS One. 2015 Oct 20;10(10):e0138062. doi: 10.1371/journal.pone.0138062. 
      eCollection 2015.